IOVA
Live chart
What they do
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced.
For information only · Important disclosures
Grades vs sector
No sector grades for IOVA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.76 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.20 vs trailing $-0.69. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score 18.1 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $263.5M | $-391.0M | $-336.2M |
| 2024 | $164.1M | $-372.2M | $-364.0M |
| 2023 | $1.2M | $-444.0M | $-384.1M |
| 2018 | $0 | – | – |
| 2017 | $0 | – | – |
| 2016 | $0 | – | – |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.13 | -0.11 | +18.4% |
| 2026-05-07 | -0.15 | -0.19 | -23.8% |
| 2026-02-24 | -0.18 | -0.18 | -2.0% |
| 2025-11-06 | -0.26 | -0.25 | +2.9% |
| 2025-08-07 | -0.28 | -0.33 | -19.4% |
| 2025-05-08 | -0.24 | -0.36 | -52.3% |
| 2025-02-26 | -0.27 | -0.26 | +2.9% |
| 2024-11-07 | -0.30 | -0.28 | +7.2% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $99.3M | +65.7% |
| 2026-03-31 | $71.4M | – |
| 2025-12-31 | $86.8M | – |
| 2025-09-30 | $67.5M | – |
| 2025-06-30 | $60.0M | – |
Analyst actions
PT $18
PT $11
PT $18
PT $20
PT $15
PT $10
Stats refreshed 2026-10-21 11:27:41 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026